Redox-responsive dasatinib-containing hyaluronic acid prodrug and co-delivery of doxorubicin for cancer therapy

Yin Ku Lin, Shiu Wei Wang, Ren Shen Lee*

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

3 Scopus citations

Abstract

Redox-responsive prodrugs were synthesized by conjugating dasatinib (Das)/cholesterol (Chol) to hyaluronic acid (HA) via the cystamine dihydrochloride (Cys), and hexamethylene diamine (Hda) linkers. In a redox environment (10 mM dithiothreitol, DTT), a substantial amount of the grafted Das was released and faster than that observed under physiological conditions. The cytotoxicity of redox-sensitive HA-Cys-P(SSDas/CCChol) was greater than that of redox-insensitive HA-Hda-PCCDas. Flow cytometry showed that the uptake of HA-targeted DOX–encapsulated micelles was faster than that of free DOX.

Original languageEnglish
Pages (from-to)1329-1343
Number of pages15
JournalInternational Journal of Polymeric Materials and Polymeric Biomaterials
Volume70
Issue number18
DOIs
StatePublished - 2021

Bibliographical note

Publisher Copyright:
© 2020 Taylor & Francis Group, LLC.

Keywords

  • Prodrug
  • dasatinib
  • hyaluronic acid
  • redox-responsive

Fingerprint

Dive into the research topics of 'Redox-responsive dasatinib-containing hyaluronic acid prodrug and co-delivery of doxorubicin for cancer therapy'. Together they form a unique fingerprint.

Cite this